UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 148

Sortiert nach

Plasma processing conditions substantially influence circulating microRNA biomarker levels

PloS one, 2013-06, Vol.8 (6), p.e64795-e64795

2013

Volltextzugriff (PDF)

Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition

Science signaling, 2019-02, Vol.12 (567)

2019

Volltextzugriff (PDF)

Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial

Journal of clinical oncology, 2013-04, Vol.31 (11), p.1415-1421

2013

Volltextzugriff (PDF)

Validation and Implementation of Targeted Capture and Sequencing for the Detection of Actionable Mutation, Copy Number Variation, and Gene Rearrangement in Clinical Cancer Specimens

The Journal of molecular diagnostics : JMD, 2014, Vol.16 (1), p.56-67

2014

Volltextzugriff (PDF)

Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma

Journal for immunotherapy of cancer, 2020-07, Vol.8 (2), p.e001009

2020

Volltextzugriff (PDF)

Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes

The Annals of thoracic surgery, 2008-11, Vol.86 (5), p.1632-1639

2008

Volltextzugriff (PDF)

Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients

Cancer medicine (Malden, MA), 2022-11, Vol.11 (22), p.4104-4111

2022

Volltextzugriff (PDF)

Estrogen signaling in lung cancer: an opportunity for novel therapy

Cancers, 2012-09, Vol.4 (4), p.969-988

2012

Volltextzugriff (PDF)

Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome

BMC cancer, 2019-01, Vol.19 (1), p.70-9, Article 70

2019

Volltextzugriff (PDF)

Detection of HPV in oral rinse samples from OPSCC and non-OPSCC patients

BMC oral health, 2015-10, Vol.15 (1), p.126-126, Article 126

2015

Volltextzugriff (PDF)

Anti-PD-1 and Anti-PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes

Diabetes care, 2015-09, Vol.38 (9), p.e137-e138

2015

Volltextzugriff (PDF)

Prognostic Value of Early Fluorodeoxyglucose-Positron Emission Tomography Response Imaging and Peripheral Immunologic Biomarkers: Substudy of a Phase II Trial of Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung Cancer

Advances in radiation oncology, 2022-03, Vol.7 (2), p.100857-100857, Article 100857

2022

Volltextzugriff (PDF)

MYCN drives chemoresistance in small cell lung cancer while USP7 inhibition can restore chemosensitivity

Genes & development, 2020-09, Vol.34 (17-18), p.1210-1226

2020

Volltextzugriff (PDF)

A Phase II study of nab-Paclitaxel (nab-P) in patients with advanced non-small cell lung cancer with EGFR mutations after frontline tyrosine kinase inhibitor therapy

Cancer treatment and research communications, 2021, Vol.28, p.100416-100416, Article 100416

2021

Volltextzugriff (PDF)

A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer

BMC cancer, 2012-10, Vol.12 (1), p.449-449, Article 449

2012

Volltextzugriff (PDF)

Phase II Study of Daily Sunitinib in FDG-PET-Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation

Clinical cancer research, 2010-11, Vol.16 (21), p.5260-5268

2010

Volltextzugriff (PDF)

Antagonism of Platelet-Derived Growth Factor Receptor in Non–Small Cell Lung Cancer: Rationale and Investigations

Clinical cancer research, 2007-08, Vol.13 (15), p.4632s-4636s

2007

Volltextzugriff (PDF)

Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN

Clinical cancer research, 2017-05, Vol.23 (10), p.2442-2450

2017

Volltextzugriff (PDF)

A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors

Investigational new drugs, 2018-10, Vol.36 (5), p.836-847

2018

Volltextzugriff (PDF)

Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility

Journal of thoracic oncology, 2018-05, Vol.13 (5), p.649-659

2018

Volltextzugriff (PDF)

Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.145-151

2017

Volltextzugriff (PDF)

Value‐Based Care in Lung Cancer

The oncologist (Dayton, Ohio), 2016-08, Vol.21 (8), p.903-906

2016

Volltextzugriff (PDF)

Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II Study

Clinical lung cancer, 2023-05, Vol.24 (3), p.218-227

2023

Volltextzugriff (PDF)

An Open-Label, Phase II Study of the Polo-like Kinase-1 (Plk-1) Inhibitor, BI 2536, in Patients with Relapsed Small Cell Lung Cancer (SCLC)

Lung cancer (Amsterdam, Netherlands), 2017-02, Vol.104, p.126-130

2017

Volltextzugriff (PDF)

Sarcoidosis Presenting as Isolated Anasarca and Hypercalcemia

The American journal of medicine, 2019-01, Vol.132 (1), p.e13-e14

2019

Volltextzugriff (PDF)

1 – 25 von 148

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(136)
Mit Volltextzugriff
(127)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(148)
Japanisch
(16)

Erscheinungsjahr

n.n

Thema

Science & Technology
(80)
Life Sciences & Biomedicine
(78)
Humans
(68)
Male
(40)
Female
(38)
Oncology
(30)
Middle Aged
(27)
Aged
(26)
Adult
(20)
Biological And Medical Sciences
(14)
Treatment Outcome
(14)
Lung Neoplasms - Drug Therapy
(13)
Medical Sciences
(13)
Patients
(11)
Retrospective Studies
(11)
Gastroenterology & Hepatology
(10)
Lung Neoplasms - Pathology
(10)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(9)
Carcinoma, Non-Small-Cell Lung - Pathology
(9)
Clinical Trials
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Plasma processing conditions substantially influence circulating microRNA biomarker levels

Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition

Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial

Validation and Implementation of Targeted Capture and Sequencing for the Detection of Actionable Mutation, Copy Number Variation, and Gene Rearrangement in Clinical Cancer Specimens

Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma

Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes

Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients

Estrogen signaling in lung cancer: an opportunity for novel therapy

Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome

Detection of HPV in oral rinse samples from OPSCC and non-OPSCC patients

Anti-PD-1 and Anti-PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes

Prognostic Value of Early Fluorodeoxyglucose-Positron Emission Tomography Response Imaging and Peripheral Immunologic Biomarkers: Substudy of a Phase II Trial of Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung Cancer

MYCN drives chemoresistance in small cell lung cancer while USP7 inhibition can restore chemosensitivity

A Phase II study of nab-Paclitaxel (nab-P) in patients with advanced non-small cell lung cancer with EGFR mutations after frontline tyrosine kinase inhibitor therapy

A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer

Phase II Study of Daily Sunitinib in FDG-PET-Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation

Antagonism of Platelet-Derived Growth Factor Receptor in Non–Small Cell Lung Cancer: Rationale and Investigations

Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN

A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors

Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility

Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer

Value‐Based Care in Lung Cancer

Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II Study

An Open-Label, Phase II Study of the Polo-like Kinase-1 (Plk-1) Inhibitor, BI 2536, in Patients with Relapsed Small Cell Lung Cancer (SCLC)

Sarcoidosis Presenting as Isolated Anasarca and Hypercalcemia

Suchergebnisse filtern